Purpose: The aim of our study is to evaluate the preclinical therapeutic activity and mechanism 24 of action of BEZ235, a dual PI3K/mTOR inhibitor, in combination with dexamethasone in ALL. 25
Introduction
leads to increased PI3K/AKT pathway activity and has also been associated with poor 98 outcomes (9, 10, 12, 16). PTEN is a negative regulator of the PI3K/AKT/mTOR pathway by 99 dephosphorylating phosphatidylinositol-3,4,5-triphosphate (PIP 3 ) to phosphatidylinositol-4,5-100 biphosphate (PIP 2 ) counteracting the action of PI3K and eliminating AKT recruitment to the cell 101 membrane where it is phosphorylated by phosphoinositide-dependent protein kinase (PDK1) at 102
Thr308 and by mTORC2 at Ser473 to become activated (17). Activated AKT phosphorylates 103 over 100 different substrates ultimately promoting increased cell survival, proliferation, growth, 104 protein synthesis, and metabolism (8, 17, 18) . 105
As constitutive activation of the PI3K/AKT/mTOR pathway occurs so frequently in T-ALL 106 and is associated with treatment resistance, this makes it an attractive target to improve 107 treatment responses in this disease. We and others previously demonstrated that rapamycin 108 enhanced dexamethasone activity in in vitro and in vivo models of T-ALL (19, 20) . Despite the 109 promising activity seen with the latter combination, the immunosuppressive effects of rapamycin 110 in combination with dexamethasone was concerning and therefore not pursued further (20) . 111
Over the last decade, various targeted inhibitors of the PI3K/AKT/mTOR pathway have been 112
developed. The first to enter clinical trials was BEZ235, a dual PI3K/mTOR inhibitor which is 113 currently on hold in development due to low oral bioavailability after Phase I/II clinical trials in 114 adults with solid and hematological malignancies as a single agent and in combination (21-25). 115
As a single agent, BEZ235 was well-tolerated in adult leukemia patients (21), providing a 116 possible alternative to rapamycin. In this study, we show that BEZ235 increased 117 dexamethasone-induced apoptosis through increasing BIM in T-ALL models. This activity is 118 due to BEZ235 inhibition of AKT1, which is a crucial mediator suppressing BIM expression in 119 response to dexamethasone. We also show that BEZ decreases MCL-1 through a mechanism 120 distinctive from AKT inactivation. The decrease in MCL-1 by BEZ235 may represent importance 121 in T-ALL with PTEN mutation/deletion, suggesting that the targeting of multiple kinases in this 122 pathway will be critical to reverse GC resistance in pediatric patients with T-ALL. L-glutamine, 5µg/mL insulin, and 20% heat-inactivated fetal bovine serum (FBS). Nalm-6 (pre-B 134
ALL, obtained from Deutsche Sammlung von Mikroorganismem und Zellkulturen (DSMZ), 135
German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany), and RS4;11 136 (pre-B ALL), T-ALL cell lines (CCRF-CEM, MOLT-3, and MOLT-4) from American Type Culture 137
Collection (ATCC, Manassas, VA) were cultured in RPMI-1640 medium (Thermo-Scientific, 138
Waltham, MA) supplemented with 10% heat-inactivated FBS. All cell lines were maintained and 139 treated with drugs in a 37˚C incubator with 5% O 2 (bone marrow-level hypoxia), 5% CO 2 , and 140 90% N 2 . Karyotype information of the cell lines is included in Supplementary Table 1. Cell line 141 identities were confirmed after each expansion and prior to freezing by short tandem repeat 142 (STR) profiling. Profiles for each cell line were unique except for pairs of cell lines established 143 from the same patient at different stages of the disease (COG-LL-329h and COG-LL-332h, 144
MOLT-3 and MOLT-4), and were verified in the COG cell line + Xenograft STR database 145 (www.COGcell.org). All cultures were confirmed to be free of mycoplasma and epstein-barr 146 virus (EBV) contamination. Studies using tissues from human subjects were approved by the 147
Institutional Review Board (IRB) of Texas Tech University Health Sciences Center. 148
Primary Cells 150
Clinical specimens were obtained with consent via a biobanking protocol approved by 151 the TTUHSC committee for protection of human subjects. 3mM L-glutamine, 5µg/mL insulin, 20% heat-inactivated fetal bovine serum (FBS), recombinant 162 IL-7 (10ng/mL; R&D Systems, Minneapolis, MN, USA), recombinant stem cell factor (50ng/mL; 163 R&D Systems), and recombinant Flt-3 ligand (20ng/mL; R&D Systems). All primary cells were 164 maintained and treated with drugs in a 37˚C incubator with 5% O 2 (bone marrow-level hypoxia) 165 (26, 27), 5% CO 2 , and 90% N 2 . Cytotoxicity experiments were performed in 24 well plates. 166
Viability of the cells was assessed by flow cytometry after staining with the FITC Annexin V 167 Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA) following manufacturer's 168 protocol. Viability was calculated as the percent of cells not staining for Annexin V or Propidium 169
Iodide. 170 171

Cytotoxicity, Apoptosis and Cell Cycle Assays 172
The in vitro cytotoxic activities of dexamethasone, BEZ235, and the BEZ235 plus 173 dexamethasone combination were determined using the DIMSCAN digital imaging microscopy 174 cytotoxicity system as described previously (28). One day prior to drug addition, cells were 175
Research. Laboratories, Burlingame, CA) according to manufacturer's instructions. The sections were 188 examined using a light microscope (BX51; Olympus, Tokyo, Japan). Images were capture 189 using CellSens® Standard 1.6 (Olympus, Tokyo, Japan). expression, and in vivo leukemia progression was performed using Student's t-test. Tests were 242 considered significant at P < 0.05. Mouse EFS was graphically represented by Kaplan-Meier 243 analysis, and survival curves were compared by log-rank test; P < 0.05 were considered 244 significant. The plotting and statistical analysis of the data was performed using GraphPad 245 Prism TM (GraphPad Software, La Jolla, CA, USA). 246
247
Results
248
BEZ235 enhances dexamethasone in vitro and in vivo cytotoxicity preferentially in T-ALL 249
We first examined the cytotoxic activity of BEZ235 and dexamethasone, as single 250 agents and in combination, in 7 T-ALL cell lines and 5 B-ALL cell lines, all of which express 251 functional GC receptor ( Supplementary Fig. 1 ). BEZ235 noticeably enhanced dexamethasone 252 cytotoxic activity in 5/7 T-ALL models (Fig. 1A) . Combination indices (CIs) were calculated for 253 each cell line to determine synergy. In the T-ALL cell lines, those 5/7 models were 254 characterized by a CI value less than 0.3, indicating strong synergy. Four out of five of those 255 synergistic models had CI values less than 0.1, indicating very strong synergy. The two cell 256 lines with non-synergistic CI values, COG-LL-329h and COG-LL-332h, were derived from the 257 same patient at diagnosis and relapse respectively and cytotoxicity appeared to be primarily 258 driven by BEZ235. In primary T-ALL lymphoblasts, BEZ235 plus dexamethasone also 259 demonstrated significantly greater anti-leukemic activity when compared with DMSO, BEZ235, 260 or dexamethasone alone (Fig. 1B, P<0 .01). Of the B-ALL cell lines, only NALM-6 was 261 characterized by a CI less than 0.3, consistent with our previous data using rapamycin ( plus dexamethsoneshowed significant reduction in weight compared with mice treated with 280 vehicle, BEZ235, or dexamethasone alone (Fig. 2C) . 281
In a separate study, event-free survival (EFS) in response to these agents was assessed 282
in systemic xenograft models of T-and B-ALL. In the systemic T-ALL patient-derived xenograft 283 COG-LL-317x, BEZ235 plus dexamethasone also increased EFS compared with 284 dexamethasone alone (Fig. 2D ). While treatment with dexamethasone alone significantly 285 prolonged EFS in the systemic B-ALL model RS4;11, there was no significant increase in 286 survival in mice treated with BEZ235 plus dexamethasone (Fig. 2E) . 287
288
BEZ235 enhances dexamethasone-induced apoptosis 289
GCs by themselves exert their anti-leukemic activity through inducing both apoptosis 290 and cell cycle arrest (32). A cell cycle analysis in the COG-LL-317h T-ALL cell line revealed an 291 increase in G 0 /G 1 and decrease in S phase cell populations following treatment with BEZ235, 292 dexamethasone, or the BEZ235 plus dexamethasone combination ( Supplementary Fig. 2) . 293
However, G 0 /G 1 arrest was not significantly greater after treatment with BEZ235 plus 294 dexamethasone compared with either single agent alone; indicating the increased cytotoxic 295 activity of BEZ235 plus dexamethasone is not due to cell cycle arrest. Therefore, apoptosis was 296 assessed by measuring Annexin V positivity following treatment with BEZ235, dexamethasone, 297 or BEZ235 plus dexamethasone in T-ALL model COG-LL-317h. As single agents compared 298 with vehicle, only dexamethasone induced a small increase in percentage of apoptotic 299 lymphoblasts ( Fig. 3A & 3B ). BEZ235 as a single agent had no significant effect on induction of 300 apoptosis compared with vehicle. Treatment with BEZ235 plus dexamethasone, however, 301 significantly increased the percentage of apoptotic lymphoblasts when compared with vehicle, 302 dexamethasone, or BEZ235 alone. In contrast, RS4;11, a dexamethasone-sensitive B-ALL 303 model, demonstrated a robust apoptotic response to dexamethasone alone, but did not further 304 increase with the addition of BEZ235 (Fig. 3A & 3B) . Surprisingly, the addition of BEZ235 305
Research. significantly decreased the percentage of apoptotic lymphoblasts compared with 306 dexamethasone only treated lymphoblasts. In COG-LL-317h, activation of caspases 9 and 3 307 were assessed following treatment by western blotting for their respective cleavage products. 308
Treatment with BEZ235 plus dexamethasone led to increased cleavage of both caspase 9 and 309 caspase 3 while no cleavage of caspases was detected in BEZ235, dexamethasone, or vehicle 310 treated lymphoblasts (Fig. 3C ). These data show that BEZ235 plus dexamethasone anti-311 leukemic activity is primarily working through increasing apoptosis. 312
313
BEZ235 enhances dexamethasone-induced apoptosis through increased expression of 314 the pro-apoptotic BCL-2 protein BIM 315
The pro-apoptotic BCL-2 family protein BIM (encoded by BCL2L11) is an indirect 316 glucocorticoid target and major mediator of glucocorticoid-induced apoptosis (33-37). 317
Consequently, in both preclinical models and primary lymphoblasts, there are inferior responses 318 to GCs and poorer prognosis associated with reduced increases in BIM expression following 319 GC exposure (38, 39) . We therefore examined the effect of BEZ235 on dexamethasone-320 induced BIM expression in the BEZ235 plus dexamethasone responsive T-ALL cell line COG-321 LL-317h following treatment and compared with the dexamethasone-sensitive B-ALL cell line 322 RS4;11. After treating COG-LL-317h lymphoblasts with BEZ235, dexamethasone, or BEZ235 323 plus dexamethasone, there was an observed increase in expression of the three dominant 324 isoforms of BIM with BEZ235 plus dexamethasone treatment compared with dexamethasone 325 only treament at both 24 and 36 hours (Fig. 4A) . Correspondingly, this was associated with a 326 BEZ235 plus dexamethasone combination-induced increase in BCL2L11 also at 24 and 36 327 hours (Fig. 4B) . The increase in BIM expression was also observed in two other BEZ235 plus 328 dexamethasone combination responsive T-ALL cell lines (CCRF-CEM and TX-LY-172h) 329 demonstrating it to be a common response in T-ALL models (Fig. 4A) . In contrast to this 330 observation, the B-ALL cell line RS4;11, showed increases in the three BIM isoforms when 331
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on April 13, 2017. © 2015 American Association for Cancer clincancerres.aacrjournals.org Downloaded from treated with dexamethasone, but BIM expression was not further increased with BEZ235 plus 332 dexamethasone (Fig. 4C) . In fact, there was a decrease in BIM expression at all three time 333 points, which is consistent with the reduction in apoptosis seen earlier. BCL2L11 expression, 334 however, was not significantly different between dexamethasone and BEZ235 plus 335 dexamethasone treated lymphoblasts, indicating that the further decrease in BIM protein 336 following treatment with BEZ235 plus dexamethasone relative to dexamethasone alone is due 337 to the changes in stability of the protein (Fig. 4D) . A similar trend was observed in another B-338 ALL cell line COG-LL-319h, although dexamethasone had minimal impact on BIM expression as 339 a single agent (Fig. 4C) . Splenic tissue isolated from mice engrafted with COG-LL-317h and 340 treated with agents for 7 days were fixed and stained with antibody against BIM. Mice treated 341 with BEZ235 plus dexamethasone demonstrated increased BIM staining compared to mice 342 treated with vehicle or either single agent alone, consistent with data obtained from in vitro 343 studies (Fig. 4E) . 344
As BIM (encoded by BCL2L11) is necessary for dexamethasone-induced apoptosis, we 345 investigated whether it contributes to BEZ235 plus dexamethasone anti-leukemic activity. Using 346 a small-interfering RNA (siRNA) against BCL2L11, BCL2L11 was knocked-down in COG-LL-347 317h (Fig. 5A ) and the changes in apoptosis and cytotoxicity in response to BEZ235, 348 dexamethasone, or BEZ235 plus dexamethasone were observed. Following treatment with 349 BEZ235 plus dexamethasone, BCL2L11 knockdown lymphoblasts showed a significant 350 reduction in caspase 3 cleavage compared with non-targeting siRNA control (Fig. 5A) . 351 Correspondingly, both apoptosis (Fig. 5B) and cytotoxicity ( BEZ235, we also investigated the phosphorylation status of mTOR complex 1 (mTORC1) 384 substrates S6K1 and 4EBP1 in T-and B-ALL models as mTORC1 activity could account for 385 BIM suppression as well. However, a noticeable association between mTORC1 activation of 386 BIM expression was not observed, suggesting that AKT primarily mediates suppression of GC-387 induced apoptosis (Supplementary Fig. 3) . 388
Although BEZ235 inhibits phosphorylation and activation of various components of the 389 PI3K/AKT/mTOR pathway, there are limited data describing the effects GCs have on this 390 pathway in human ALL. To demonstrate the effect of dexamethasone, BEZ235, and BEZ235 391 plus dexamethasone on this pathway, COG-LL-317h lymphoblastswere treated for 12, 24, and 392 36 hours before assessing expression and phosphorylation status of AKT, FOXO, mTOR, 393 S6K1, S6, and 4EBP1 ( Supplementary Fig. 3B ). Interestingly, with dexamethasone treatment, 394
we found a time-dependent increase in phosphorylation of AKT at both Ser473 and Thr308. 395
BEZ235 as a single agent and in combination with dexamethasone potently reduced 396
phosphorylation of AKT at both sites to undetectable levels as well as one of its targets FOXO4. 397
In contrast, mTORC1 activity as indicated by phosphorylation of its target, S6K1 showed a time-398 dependent reduction in phosphorylation by dexamethasone alone. The ability of 399 dexamethasone to reduce activation of mTORC1 and its targets further provide evidence that 400 AKT plays a role in glucocorticoid resistance. 401
Of the three AKT isoforms, AKT1 is the most dominant isoform expressed ubiquitously 402 throughout all tissues and thought to be the primary isoform involved in regulating cell survival 403 (40). To investigate the role of AKT1 on dexamethasone activity, COG-LL-317h lymphoblasts 404
were transfected with siRNA specifically against AKT1. AKT1 knockdown decreased AKT 405 activity for at least 48 hours (Fig. 5D) . Compared with non-targeting control siRNA, siRNA 406 against AKT1 demonstrated increased expression of the 3 BIM isoforms following 24 hours of 407 dexamethasone or BEZ235 plus dexamethasone treatment (Fig. 5E ). Despite observing an 408 increase in BIM, however, AKT1 knockdown led to only a minimal, but statistically significant 
MCL-1 downregulation by BEZ235 increases dexamethasone response in T-ALL 414
With only a modest increase in dexamethasone cytotoxicity after AKT1 knockdown, it is 415 likely that another mechanism plays a role in BEZ235 plus dexamethasone cytotoxicity. It has 416 been previously suggested that the anti-apoptotic BCL-2 family protein MCL-1 plays a role in 417 glucocorticoid resistance in ALL (41, 42). In our studies, when comparing BIM protein 418 expression between COG-LL-317h and RS4;11 after treatment with BEZ235, dexamethasone, 419 or BEZ235 plus dexamethasone, the increased BIM expression observed after treatment in 420 COG-LL-317h was less than basal expression of BIM in RS4;11, suggesitng that increasing 421 BIM, although necessary, is not sufficient to induce apoptosis in models with 422 hyperphosphorylated AKT (Supplementary Fig. 4B ). We therefore hypothesized that the 423 increased glucocorticoid-induced BIM expression following AKT1 knockdown is being 424 sequestered by MCL-1, further inhibiting the ability to induce dexamethasone-induced 425 apoptosis. No distinctive differences were seen in constitutive MCL-1 levels between sensitive 426 and insensitive cell lines or T-and B-ALL cell lines (Fig. 6A) . However, as observed with 427 various other PI3K/AKT/mTOR pathway inhibitors (43, 44), a strong reduction in MCL-1 428 expression was observed in COG-LL-317h following treatment with BEZ235, suggesting MCL-1 429 plays a role in the BEZ235 plus dexamethasone cytotoxic activity in our models (Fig. 6B) they do not have a significant role in the combination mechanism in this model (Fig. 6B) . 436
Knockdown of MCL1 by siRNA increased dexamethasone-induced cytotoxicity (Supplementary 437 Fig. 4D ). Additionally, MCL1 knockdown was able to induce apoptosis and enhance 438 dexamethasone-induced apoptosis (Fig. 6D) . Despite the ability of BEZ235 to decrease MCL-1 439 protein expression, AKT1 knockdown was unable to recapitulate this effect ( Supplementary Fig.  440 4E), suggesting AKT1 inhibition is not regulating MCL-1 and explains the lack of robust cytotoxic 441 response observed previously. As MCL-1 can bind to and sequester BIM, we treated COG-LL-442 317h with BEZ235, dexamethasone, or BEZ235 plus dexamethasone before 443 immunoprecipitating for MCL-1. Immunoprecipitation of MCL-1 confirmed that MCL-1 was 444 interacting with BIM in our model and the increased BIM due to dexamethasone or BEZ235 plus 445 dexamethasone treatment was also being sequestered by MCL-1 (Fig. 4E) , indicating that MCL-446 1 is also playing a role in GC resistance. BEZ235 treatment also decreased MCL-1 protein 447 expression in RS4;11 lymphoblasts ( Supplementary Fig. 5A ), but MCL1 knockdown by siRNA 448 in RS4;11 ( Supplementary Fig. 5B ) did not significantly increase apoptosis ( Supplementary Fig.  449 5C). Similarly, MCL1 knockdown led to small increases in dexamethasone cytotoxicity, but 450 demonstrated only small effects at clinically achievable concentrations of dexamethasone 451 (Supplementary Fig. 5D ). These data suggest that decreased MCL-1, although a common 452 effect of BEZ235 across different ALL cell lines, only alters apoptotic response and cytotoxicity 453 in models with low BIM expression and PTEN mutations. 
known mediator of GC-induced apoptosis, which is consistent with previous studies implicating 462 AKT in GC resistance and suppression of BIM expression in T-ALL models (46, 47). We also 463 examined the downstream activation of mTORC1 and observed that dexamethasone was able 464 to reduce mTORC1 activation independent of AKT. The observation of increased AKT 465 phosphorylation upon dexamethasone treatment may indicate there is activation of the known 466 negative feedback loop consisting of S6K1 phosphorylation and downregulation of IRS1 (48). 467
This activity could also contribute to GC resistance by increasing AKT activation and therefore 468 further inhibiting apoptosis, and warrants further investigation. It is also worth noting that 469 inhibition of mTORC1 by dexamethasone treatment over time correlated with progressive G 0 /G 1 470 arrest, suggesting that mTORC1 inhibition may be involved in the cytostatic effects of GCs. 471
This would indicate that the cytotoxic and cytostatic mechanisms of GCs may be independent of 472 each other. 473
The PI3K/AKT pathway appears to play a critical role in T-ALL as common mutations in 474 T-ALL (NOTCH1/PTEN) can lead to constitutive activation of this pathway and could account for 475 the high frequency of AKT activation observed in primary T-ALL patient samples (15). This is 476 particularly highlighted by the contrast in cytotoxic activity observed between T-ALL and B-ALL 477 models in response to treatment with BEZ235 plus dexamethasone. In T-ALL models, BEZ plus 478 dexamethasone synergistic activity appeared to be independent of PTEN or AKT status, as 479 evidenced by the increased BIM expression and cytotoxic activity observed in TX-LY-172h, a 480 treatment. In T-ALL with substantial reductions in BIM, as observed in PTEN-null models, this 514 may be necessary to achieve GC-induced apoptosis and explains why AKT1 knockdown was 515 insufficient to induce apoptosis in PTEN-null T-ALL. As suggested by Ploner et al., by 516 regulation of a "BCL-2 rheostat" we may be able to enhance GC responses in GC resistant ALL 517 (42). 518 BEZ235 potentiates dexamethasone cytotoxicity in models of T-ALL by increasing BIM 519 and decreasing MCL-1, providing a possible adjunct in current T-ALL treatment protocols 520 (Mechanism summarized in Supplementary Fig. 6 ). Our data are in agreement with a previous 521 cell line-study of BEZ235 as a potential therapy modifier in GC resistant T-ALL (49). 
